US Patent 10,039,804: Vancomycin and N-Acetyl-D-Alanine Formulation Patent Analysis
US Patent 10,039,804 protects aqueous vancomycin compositions containing N-acetyl-D-alanine, with additional claim coverage for amino acids, polyethylene glycol or ethanol, defined pH ranges, concentration ratios, and parenteral treatment. The narrowest and most commercially specific embodiment is a 0.5% w/V vancomycin formulation containing L-lysine and N-acetyl-D-alanine at a 1:20:30 molar ratio, pH 4.5-5.5, and 1.8% V/V polyethylene glycol.[1]
The patent is primarily a formulation and method-of-treatment patent. It does not claim vancomycin as an active ingredient, nor does it claim every vancomycin product. Infringement depends on whether a competing product contains the claimed excipient combination and falls within the specified concentration, ratio, pH, solvent, and administration limitations.
What does US Patent 10,039,804 protect?
The patent protects aqueous pharmaceutical compositions combining vancomycin with N-acetyl-D-alanine. The claims divide into five coverage groups:
| Coverage group |
Claims |
Principal limitations |
| Basic N-acetyl-D-alanine compositions |
1-2 |
Vancomycin at about 0.5% or 5% w/V; specified N-acetyl-D-alanine ratios |
| Amino-acid compositions |
3-6 |
Vancomycin, N-acetyl-D-alanine and an amino acid |
| Organic-solvent compositions |
7-8 |
Ethanol or polyethylene glycol, up to 50% V/V |
| Combination formulation |
9-11 |
Concentration, pH, amino acid, ratio and solvent limitations |
| Treatment methods |
12-17 |
Administration of the claimed aqueous formulations, including parenteral use |
The independent composition claims are claims 1, 2, 3, 7 and 9. Claims 12, 16 and 17 are independent or functionally broad method claims, while the other claims narrow the composition or treatment requirements.
What are the independent claims in US 10,039,804?
Claims 1 and 2: concentration-specific compositions
Claim 1 covers an aqueous composition comprising:
- vancomycin;
- N-acetyl-D-alanine;
- a N-acetyl-D-alanine-to-vancomycin molar ratio of about 5:1 to about 40:1; and
- about 0.5% w/V vancomycin.
Claim 2 covers a separate concentration band:
- about 5% w/V vancomycin; and
- N-acetyl-D-alanine at a molar ratio of about 0.1:1 to about 10:1 relative to vancomycin.
These claims do not require an amino acid, polyethylene glycol, ethanol, or a specified pH. Their principal limitation is the combination of vancomycin concentration and N-acetyl-D-alanine ratio.
A formulation containing 0.5% vancomycin and a 5:1 to 40:1 ratio may fall within claim 1 even if it lacks lysine or an organic solvent. A formulation containing 5% vancomycin must satisfy the distinct ratio range in claim 2.
Claim 3: broad amino-acid combination
Claim 3 covers an aqueous formulation containing:
- vancomycin;
- N-acetyl-D-alanine; and
- an amino acid.
The claim does not identify a particular amino acid or establish a concentration range. Its scope is therefore materially broader than claims 4-6, although its enforceability depends on the meaning of “amino acid” in the patent specification and prosecution history.
Claim 7: solvent-containing composition
Claim 7 covers vancomycin, N-acetyl-D-alanine, and an organic solvent selected from:
- ethanol; or
- polyethylene glycol.
Claim 8 narrows the solvent content to up to 50% V/V. The wording “up to 50% V/V” potentially covers formulations containing no more than 50% solvent, subject to the claim’s other requirements and ordinary claim-construction principles.
Claim 9: principal combination claim
Claim 9 is the central multi-parameter formulation claim. It requires:
- 0.5-15% w/V vancomycin;
- vancomycin-to-N-acetyl-D-alanine molar ratio of about 1:1 to 1:40;
- pH of about 3-6;
- one of eight specified amino acids;
- amino acid-to-vancomycin molar ratio of about 1:1 to 30:1; and
- up to 50% V/V pharmaceutically acceptable organic solvent.
The listed amino acids are:
- D-serine;
- D-leucine;
- D-valine;
- L-lysine;
- D-lysine;
- L-arginine;
- D-ornithine; and
- L-ornithine.
Claim 10 limits the organic solvent to polyethylene glycol. Claim 11 narrows the formulation to the disclosed lysine/polyethylene glycol embodiment.
Which claim is most commercially important?
Claim 11 is the most product-specific claim. It covers:
- 0.5% w/V vancomycin;
- L-lysine;
- N-acetyl-D-alanine;
- vancomycin:L-lysine:N-acetyl-D-alanine at 1:20:30;
- pH 4.5-5.5; and
- 1.8% V/V polyethylene glycol.
The claim has strong technical specificity but a correspondingly narrow literal scope. A competitor could seek design-around protection by changing one or more of the following:
| Design-around variable |
Claim 11 impact |
| Vancomycin concentration |
Moving materially away from about 0.5% may avoid the claim |
| Amino acid |
Substituting another amino acid may avoid claim 11 but not necessarily claim 9 |
| Amino-acid stereochemistry |
Replacing L-lysine with D-lysine changes the express limitation |
| Molar ratio |
Changing any of the 1:20:30 ratios may avoid literal infringement |
| pH |
Moving outside pH 4.5-5.5 may avoid claim 11 |
| Polyethylene glycol concentration |
Changing 1.8% V/V may avoid claim 11 |
| N-acetyl-D-alanine |
Removing or replacing it avoids the central inventive combination |
The broader claims create residual risk even where claim 11 is avoided. A formulation outside claim 11 may still implicate claims 3, 7 or 9.
How broad is the patent’s formulation coverage?
The formulation coverage is broad at the ingredient level but narrower at the numerical limitation level.
Ingredient coverage
The patent repeatedly requires N-acetyl-D-alanine. A vancomycin formulation containing only conventional buffers, stabilizers, salts or sugars is outside the literal scope of claims that require N-acetyl-D-alanine.
The amino-acid claims cover both common amino acids and specific stereoisomers. Claim 4 lists glycine, alanine, serine, leucine, valine, lysine, arginine and ornithine. Claim 5 narrows the lysine requirement to L-lysine or D-lysine.
Concentration coverage
Claims 1, 2, 6, 9 and 11 use overlapping but different concentration frameworks:
- Claim 1: about 0.5% w/V vancomycin.
- Claim 2: about 5% w/V vancomycin.
- Claim 6: about 0.5-15% w/V vancomycin.
- Claim 9: about 0.5-15% w/V vancomycin.
- Claim 11: about 0.5% w/V vancomycin.
The overlap means that a formulation may satisfy more than one claim if its ratios and excipients align. Claim 6 is particularly important because it covers a broad vancomycin concentration range and a 1:1 to 1:40 vancomycin-to-N-acetyl-D-alanine ratio, subject to the amino-acid requirement inherited from claim 3.
pH coverage
Only claims 9-15 impose a pH range. The operative range is approximately pH 3-6, with the more specific claim 11 range of pH 4.5-5.5.
A formulation outside pH 3-6 may avoid claims 9 and 14, but it could remain within claims 1-8 or 12-13 if the other limitations are met.
What patent landscape surrounds vancomycin and N-acetyl-D-alanine formulations?
The relevant patent landscape has four layers.
Core vancomycin composition patents
The core product claims concern the combination of vancomycin and N-acetyl-D-alanine. These claims are the principal barrier for an aqueous formulation using that excipient.
The highest-risk claims are:
- Claim 3, because it broadly requires vancomycin, N-acetyl-D-alanine and an amino acid.
- Claim 7, for ethanol or polyethylene glycol formulations.
- Claim 9, for the specified pH, concentration, amino-acid and solvent combination.
- Claim 12, for treatment using an aqueous vancomycin/N-acetyl-D-alanine composition.
Formulation and stability patents
Separate patent families may cover:
- vancomycin concentration and pH;
- lyophilized vancomycin;
- reconstitution systems;
- buffers and preservatives;
- infusion solutions;
- reduced degradation products;
- aggregation control;
- delivery devices;
- ready-to-use parenteral containers; and
- extended-temperature storage.
US 10,039,804 does not, based on the supplied claims, claim a lyophilized product, a container, a specific delivery device, a manufacturing process, or a defined impurity profile.
Method-of-use patents
Claims 12-17 cover treatment methods. Claim 12 is comparatively broad because it requires administration of an aqueous composition containing vancomycin and N-acetyl-D-alanine, without expressly requiring the amino acid, solvent, pH, or concentration limitations in the independent claim.
Claims 14 and 15 narrow the method to formulations corresponding to claims 9 and 11. Claim 16 specifies parenteral administration. Claim 17 requires an amount sufficient to treat the infection, which is a functional limitation rather than a fixed dose.
Manufacturing and process patents
The supplied claims do not cover:
- synthesis of vancomycin;
- synthesis of N-acetyl-D-alanine;
- blending order;
- sterilization;
- aseptic filling;
- filtration;
- container closure;
- impurity removal; or
- scale-up operations.
A competing manufacturer could therefore avoid the composition claims only if the final product does not meet the claimed formulation limitations. Changing the manufacturing process alone would not avoid infringement if the finished product contains the claimed ingredients and ratios.
What is the patent expiration date?
The exact expiration date cannot be determined from the claim text alone. US utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension and terminal disclaimers.[2]
The issue date of US Patent 10,039,804 is not the controlling expiration date. A patent issued in 2018 may expire before or after the apparent 20-year period depending on:
- the earliest priority application;
- continuation or divisional status;
- patent-term adjustment;
- patent-term extension;
- terminal disclaimers; and
- maintenance-fee status.
A definitive freedom-to-operate opinion requires the patent’s front-page priority data, USPTO Patent Center prosecution record and current maintenance status.
Is US 10,039,804 likely to be listed in the Orange Book?
The claims do not establish Orange Book listing status. Orange Book listing is tied to approved drug products and patent information submitted by the new drug application holder, not to patent ownership alone.[3]
The patent could be relevant to an approved vancomycin product only if:
- the product is approved under an applicable FDA pathway;
- the patent holder or NDA holder submitted the patent for listing;
- the patent claims an approved formulation, method of use or product; and
- FDA accepted the listing under its patent-listing rules.
Vancomycin has long-standing approved products, including injectable and oral dosage forms. That fact does not establish that this patent covers or is listed against any particular product. A patent directed to a new excipient combination may also have no Orange Book relevance if no approved product uses that combination.
What Paragraph IV risks apply?
A generic applicant could file a Paragraph IV certification against a listed patent if the applicant asserts that the patent is invalid, unenforceable or will not be infringed.[4]
For this patent, likely Paragraph IV strategies would include:
Noninfringement
A generic applicant could design around:
- N-acetyl-D-alanine;
- the claimed amino acids;
- the molar ratios;
- the pH ranges;
- polyethylene glycol or ethanol;
- the specified vancomycin concentrations; or
- the parenteral method limitations.
Invalidity
Potential invalidity theories would depend on the prosecution record and prior art, including:
- anticipation by an earlier aqueous vancomycin/N-acetyl-D-alanine formulation;
- obviousness based on known vancomycin binding to D-alanine-containing ligands;
- lack of written description for the full numerical ranges;
- lack of enablement across the claimed concentration and ratio ranges;
- indefiniteness involving “about,” “up to,” or “sufficient to treat”; and
- double patenting if related continuation claims overlap.
The technical question is whether the claimed excipient combinations and numerical ranges produced an unexpected stabilization, compatibility or therapeutic result over the closest prior art. The claims alone do not resolve that issue.
Which companies are challenging US 10,039,804?
No challenger, Paragraph IV notice, district-court action or settlement agreement can be identified from the supplied claims. A complete litigation assessment requires the patent’s assignee history, FDA Orange Book records, USPTO assignment records and federal court docket searches.
The absence of a known challenge cannot be inferred from the patent text. Generic competition against ordinary vancomycin products also does not establish a challenge to this patent because the patent is directed to a particular aqueous excipient system rather than to vancomycin generally.
What is the biosimilar risk?
Biosimilar risk is effectively not the primary issue. Vancomycin is a small-molecule antibacterial, not a biologic subject to the biosimilar pathway under the Public Health Service Act.[5]
The relevant competitive pathways are:
- abbreviated new drug applications;
- 505(b)(2) applications;
- new drug applications for reformulated products; and
- state or hospital procurement competition.
A 505(b)(2) applicant developing a new vancomycin formulation could face formulation-patent and method-of-use issues distinct from ordinary ANDA applicants.
How strong is the patent estate?
The estate appears strongest against a product that deliberately reproduces the disclosed formulation architecture:
- aqueous vancomycin;
- N-acetyl-D-alanine;
- lysine or another listed amino acid;
- acidic pH;
- polyethylene glycol or ethanol; and
- the claimed concentration and molar ratios.
The estate is weaker against:
- conventional vancomycin injection;
- lyophilized vancomycin;
- formulations without N-acetyl-D-alanine;
- formulations using a different stabilizer;
- products outside the concentration and ratio ranges; and
- products using a different pH or solvent system.
| Risk category |
Assessment based on supplied claims |
| Conventional vancomycin product |
Low direct claim risk |
| Aqueous vancomycin plus N-acetyl-D-alanine |
High |
| Same formulation plus lysine |
High |
| Same formulation plus polyethylene glycol |
High |
| Formulation with different stabilizer |
Lower |
| Lyophilized formulation |
Low under supplied claims |
| Manufacturing-process-only variation |
Does not avoid product claims if final composition is covered |
| Parenteral use of covered formulation |
High under claims 12, 14 and 16 |
What generic launch scenarios exist?
Scenario 1: conventional vancomycin generic
A conventional injectable vancomycin product without N-acetyl-D-alanine is unlikely to meet the supplied composition claims. The patent would not ordinarily block that product unless another claim or patent family reaches the formulation.
Scenario 2: ready-to-use aqueous formulation
A ready-to-use aqueous product containing N-acetyl-D-alanine presents the highest risk. The sponsor would need to compare the product’s exact:
- vancomycin concentration;
- N-acetyl-D-alanine ratio;
- amino acid;
- pH;
- solvent;
- solvent percentage; and
- route of administration
against every asserted claim.
Scenario 3: 505(b)(2) formulation
A reformulated vancomycin product could rely partly on an existing reference product while seeking approval for a distinct formulation. Patent certification, labeling and clinical-bridging issues would depend on the approved product and listed patents.
Scenario 4: design-around formulation
A competitor could reduce risk by eliminating N-acetyl-D-alanine or changing the formulation platform. That approach may create new stability, compatibility, toxicity, manufacturing or regulatory requirements.
What geographic coverage applies?
US Patent 10,039,804 provides enforceable rights only in the United States. International protection would require separate national or regional patents derived from the relevant priority or PCT family.
Potential parallel jurisdictions include:
- Europe;
- Canada;
- Japan;
- Australia;
- China;
- India; and
- other markets with vancomycin demand.
The US claims cannot establish foreign rights. A global launch assessment requires family-level review of pending, granted, expired, abandoned and lapsed counterparts.
What licensing and settlement issues should be reviewed?
No licensing deal or settlement agreement is established by the supplied claims. Commercial review should focus on:
- assignments and exclusive licenses;
- development or commercialization agreements;
- patent-family ownership;
- covenants not to sue;
- Paragraph IV settlement terms;
- authorized-generic arrangements;
- field-of-use restrictions; and
- royalty obligations tied to formulation sales.
A license covering vancomycin generally would not necessarily cover the specific N-acetyl-D-alanine composition claims. The agreement would need to identify the patent family or claim category expressly.
Key Takeaways
- US 10,039,804 is a vancomycin formulation and treatment patent centered on N-acetyl-D-alanine.
- The broadest practical composition claim is claim 3, which adds an amino acid requirement.
- Claims 7-11 create focused risk for formulations containing polyethylene glycol or ethanol.
- Claim 11 targets a specific 0.5% vancomycin, L-lysine, N-acetyl-D-alanine and polyethylene glycol formulation.
- Conventional vancomycin products without N-acetyl-D-alanine are less exposed under the supplied claims.
- The patent does not claim vancomycin synthesis, lyophilization, container systems or manufacturing processes.
- Biosimilar analysis is not the relevant framework because vancomycin is a small-molecule drug.
- The exact patent expiration date, Orange Book status, litigation record, licensing history and foreign-family scope cannot be established from the claims alone.
- Generic and 505(b)(2) risk is highest for a ready-to-use aqueous product reproducing the claimed excipient system and numerical ranges.
FAQs
Does US 10,039,804 cover all injectable vancomycin products?
No. The supplied claims require N-acetyl-D-alanine. An injectable vancomycin product without that ingredient would generally not satisfy the central composition limitations.
Can a formulation avoid the patent by using D-lysine instead of L-lysine?
It may avoid claim 11, which specifically requires L-lysine. It could remain within broader claims that expressly cover D-lysine, including claims 5 and 9.
Does changing polyethylene glycol concentration avoid infringement?
It may avoid claim 11 if the product no longer contains the claimed 1.8% V/V concentration. The product could still implicate claim 8, claim 9 or claim 10 depending on its other characteristics.
Is oral vancomycin covered by the patent?
The claims do not expressly limit the formulation to injectable use. Claims 12 and 16 create different treatment coverage, with claim 16 specifically addressing parenteral administration. Oral products require a separate element-by-element analysis.
Does the patent cover N-acetyl-L-alanine?
The claims identify N-acetyl-D-alanine. N-acetyl-L-alanine is not expressly covered by the supplied claim language and would require analysis under claim construction and possible doctrine-of-equivalents theories.
References
- U.S. Patent No. 10,039,804, claims 1-17. United States Patent and Trademark Office.
- 35 U.S.C. § 154(a)(2) (2023).
- U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations (Orange Book).
- 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (2023).
- Biologics Price Competition and Innovation Act, 42 U.S.C. § 262 (2023).
